Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Fiche publication
Date publication
septembre 2017
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FEUGIER Pierre, Pr FORNECKER Luc-Matthieu, Pr CALLANAN Mary
Tous les auteurs :
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O,
Lien Pubmed
Résumé
Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-surface area administered every 2 months for 3 years after transplantation would prolong the duration of response.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Cisplatin, administration & dosage, Combined Modality Therapy, Cytarabine, administration & dosage, Dexamethasone, administration & dosage, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunologic Factors, administration & dosage, Lymphoma, Mantle-Cell, drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Proportional Hazards Models, Rituximab, administration & dosage, Survival Analysis, Transplantation, Autologous
Référence
N. Engl. J. Med.. 2017 09;377(13):1250-1260